Literature DB >> 2876855

Presence of a diffusional barrier on metabolite kinetics: enalaprilat as a generated versus preformed metabolite.

I A de Lannoy, K S Pang.   

Abstract

Studies in the once-through perfused rat liver with the simultaneous delivery of 14 C-enalapril and its polar diacid metabolite, 3H-enalaprilat, revealed different extents of elimination (exclusively by biliary excretion) for the generated (14C-enalaprilat) and preformed (3H-enalaprilat) metabolite (18 and 5% dose) [Pang, Cherry, Terrell, and Ulm: Drug Metab. Dispos. 12, 309-313 (1984)]. The present re-examination of data provided an explanation for these discrepant observations: enalaprilat, being a polar dicarboxylic acid, encounters more of a diffusional barrier than its precursor, enalapril, an ethyl ester of enalaprilat. Programs written in Fortran 77 on mass balance relationships were employed to simulate data upon varying the diffusional clearances for drug (CLd) and metabolite [CLd(mi)] from 1 to 5000 ml/min. The metabolic and biliary intrinsic clearances for drug and metabolite were found by trial and error such that the combinations of all clearance parameters yielded data similar to enalaprilat, and 3H-enalaprilat. Our finding indicated that the diffusional clearance for enalaprilat was low (2 ml/min) compared to that of enalapril (75 ml/min). The presence of a diffusional barrier for enalaprilat retards entry of the preformed metabolite into hepatocytes but prevents efflux of the intracellularly formed generated metabolite into sinusoidal blood, thereby enhancing generated metabolite elimination.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2876855

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  13 in total

Review 1.  Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion.

Authors:  K Sandy Pang; Matthew R Durk
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-14       Impact factor: 2.745

2.  Role of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat.

Authors:  Brian C Ferslew; Kathleen Köck; Arlene S Bridges; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2014-06-23       Impact factor: 3.922

Review 3.  Clinical significance of pharmacokinetic models of hepatic elimination.

Authors:  D J Morgan; R A Smallwood
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

4.  Hepatic conjugation/deconjugation cycling pathways. Computer simulations examining the effect of Michaelis-Menten parameters, enzyme distribution patterns, and a diffusional barrier on metabolite disposition.

Authors:  S B Hansel; M E Morris
Journal:  J Pharmacokinet Biopharm       Date:  1996-04

5.  Membrane transport in hepatic clearance of drugs. I: Extended hepatic clearance models incorporating concentration-dependent transport and elimination processes.

Authors:  Y Kwon; M E Morris
Journal:  Pharm Res       Date:  1997-06       Impact factor: 4.200

6.  Membrane transport in hepatic clearance of drugs. II: Zonal distribution patterns of concentration-dependent transport and elimination processes.

Authors:  Y Kwon; M E Morris
Journal:  Pharm Res       Date:  1997-06       Impact factor: 4.200

7.  Effect of a diffusional barrier to a metabolite across hepatocytes on its kinetics in "enzyme-distributed" models: a computer-aided simulation study.

Authors:  S Miyauchi; Y Sugiyama; H Sato; Y Sawada; T Iga; M Hanano
Journal:  J Pharmacokinet Biopharm       Date:  1987-08

8.  Competition between two enzymes for substrate removal in liver: modulating effects due to substrate recruitment of hepatocyte activity.

Authors:  M E Morris; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1987-10

9.  A physiological model for renal drug metabolism: enalapril esterolysis to enalaprilat in the isolated perfused rat kidney.

Authors:  I A de Lannoy; H Hirayama; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1990-12

10.  A preliminary physiologically based pharmacokinetic model for naphthalene and naphthalene oxide in mice and rats.

Authors:  L M Sweeney; M L Shuler; D J Quick; J G Babish
Journal:  Ann Biomed Eng       Date:  1996 Mar-Apr       Impact factor: 3.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.